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Abstract
Background: Tolerance seriously impedes the application of morphine in clinical medicine. Thus, it is necessary
to investigate the exact mechanisms and efficient treatment. Microglial activation and neuroinflammation in the
spinal cord are thought to play pivotal roles on the genesis and maintaining of morphine tolerance. Activation
of adenosine monophosphate-activated kinase (AMPK) has been associated with the inhibition of inflammatory
nociception. Metformin, a biguanide class of antidiabetic drugs and activator of AMPK, has a potential anti-inflammatory
effect. The present study evaluated the effects and potential mechanisms of metformin in inhibiting microglial
activation and alleviating the antinociceptive tolerance of morphine.
Methods: The microglial cell line BV-2 cells and mouse brain-derived endothelial cell line bEnd3 cells were used.
Cytokine expression was measured using quantitative polymerase chain reaction. Cell signaling was assayed by
western blot and immunohistochemistry. The antinociception and morphine tolerance were assessed in CD-1
mice using tail-flick tests.
Results: We found that morphine-activated BV-2 cells, including the upregulation of p38 mitogen-activated
protein kinase (p38 MAPK) phosphorylation, pro-inflammatory cytokines, and Toll-like receptor-4 (TLR-4) mRNA
expression, which was inhibited by metformin. Metformin suppressed morphine-induced BV-2 cells activation
through increasing AMPK phosphorylation, which was reversed by the AMPK inhibitor compound C. Additionally,
in BV-2 cells, morphine did not affect the cell viability and the mRNA expression of anti-inflammatory cytokines.
In bEnd3 cells, morphine did not affect the mRNA expression of interleukin-1β (IL-1β), but increased IL-6 and
tumor necrosis factor-α (TNF-α) mRNA expression; the effect was inhibited by metformin. Morphine also did not
affect the mRNA expression of TLR-4 and chemokine ligand 2 (CCL2). Furthermore, systemic administration of
metformin significantly blocked morphine-induced microglial activation in the spinal cord and then attenuated
the development of chronic morphine tolerance in mice.
Conclusions: Metformin significantly attenuated morphine antinociceptive tolerance by suppressing morphine-
induced microglial activation through increasing AMPK phosphorylation.
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Background
Morphine is the most commonly used drug for the
treatment of severe pain. However, long-term morphine
treatment leads to tolerance which greatly attenuates
analgesic effect and diminishes clinical utilization. There-
fore, investigating mechanisms of morphine tolerance and
identification of solutions are of clinical significance.
Among the previous studies, mechanisms of morphine
tolerance are complex and involve many factors, such
as ion channels, receptors, cells, and neural networks
[1–3]. For a long time, extensive studies suggested that
neurons participate in the development of morphine
tolerance [3, 4]. However, compelling evidences recently
show that glia cells, especially microglia, play a pivotal
role in the initiation and maintenance of morphine
tolerance [5, 6].
Microglia in the spinal cord are significantly activated
by chronic morphine treatment. Several studies showed
that morphine induces a proinflammatory response
through binding to Toll-like receptor 4 (TLR4), leading
to initiation of the TLR4 signaling cascade, as do direct
modulators of p38 and nuclear factor-κB (NF-κB), sub-
sequently regulating the expression of multiple inflam-
mation factors [7, 8]. Other studies established that
activated microglia secrete large amounts of proinflam-
matory cytokines including interleukin-1β (IL-1β), IL-6,
and tumor necrosis factor-α (TNF-α), which could en-
hance the hyperactivity of dorsal horn neurons, induce
central sensitization, and reduce the antinociceptive
effect of morphine [9, 10]. Thus, suppression of neuro-
inflammation by inhibiting microglial activation and
proinflammatory cytokines could be a worthwhile strategy
for enhancing morphine analgesic efficacy and attenuating
morphine tolerance.
5′-Adenosine monophosphate-activated protein kinase
(AMPK), a sensor of cellular energy change, regulates
energy homeostasis and metabolic stress. Recent studies
show that AMPK regulates both energy homeostasis and
inflammatory defense [11–13]. Activation of AMPK in-
hibits ATP-consuming anabolic processes (such as protein
translation) mainly via inhibiting mammalian target of
rapamycin (mTOR) signaling [14]. AMPK activation also
inhibits mitogen-activated protein kinase (MAPK) signal-
ing. MAPK family, especially p38 mitogen-activated pro-
tein kinase (p38 MAPK) in activated microglia, have been
shown to play an important role in morphine-induced
neuroinflammation and tolerance [15]. In the brain, AMPK
activation inhibits lipopolysaccharide (LPS)-induced pro-
inflammatory cytokines expression by modulating NF-κB
in primary rat microglia [16]. AMPK activation also in-
hibits the expression of pro-inflammatory mediators in the
cerebral cortex of LPS-injected rats [11]. Thus, AMPK
may be an interesting target for neuroprotective drugs in
inflammatory conditions, such as morphine tolerance. We
hypothesized that AMPK activation may represent a novel
pharmacological treatment to reduce morphine tolerance
by suppressing morphine-induced neuroinflammation
through attenuating microglial activation.
To test our hypothesis, we used metformin, a potent
antihyperglycaemic agent that has previously been shown
to active AMPK, to assess the effect of AMPK activation
on morphine-induced microglial activation and tolerance.
Methods
Animals
Adult CD-1 mice (18–22 g) were purchased from the
Experimental Animal Center at Nanjing Medical Univer-
sity, Nanjing, China. Five to six mice per cage were housed
under pathogen-free conditions with soft bedding under
controlled temperature (22 ± 2 °C) and a 12-h light/dark
cycle (lights on at 8:00 a.m.). For each group of experi-
ments, the animals were matched by age and body weight.
Behavioral testing was performed during the light cycle
(between 9:00 a.m. and 5:00 p.m.). Mice were allowed to
acclimate to these conditions for at least 2 days before
inclusion in experiments.
Reagents
All antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA) unless stated other-
wise. IL-1β was from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) and ionized calcium binding adapter
molecule 1 (IBA-1) were from Sigma-Aldrich (St. Louis,
MO, USA) and Wako Pure Chemical Industries (Osaka,
Japan). The p65/RelA and immunofluorescence IBA-1
antibodies were from Abcam (Cambridge, MA, USA).
Immunofluorescence c-fos and calcitonin gene-related
peptide (CGRP) antibodies were from Cell Signaling
Technology (Beverly, MA, USA) and Santa Cruz Bio-
technology (Santa Cruz, CA, USA), respectively. Mor-
phine hydrochloride was purchased from Shenyang
First Pharmaceutical Factory, Northeast Pharmaceutical
Group Company (Shenyang, China). Fetal bovine serum
(FBS) and other cell culture media and supplements
were purchased from Hyclone (Logan, UT, USA). 3-
(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium
bromide (MTT) was purchased from Sunshine Biotech-
nology (Nanjing, China).
Cell preparation and stimulation
BV-2 cells mouse brain endothelial cells bEND3 were
cultured in humidified 5% CO2 at 37 °C in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% (v/v) FBS, penicillin (100 U/ml), and streptomycin
(100 U/ml) (KeyGEN). For inducing inflammasome acti-
vation, 105 cells were plated in 6-well plate overnight,
and the medium were changed to serum-free medium
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next morning and then the cells were treated with mor-
phine (200 μM) with or without metformin for 6 h. Met-
formin (4, 20, or 100 μM) was administrated 15 min
before morphine treatment. Cell extracts and precipitated
supernatants were analyzed by immunoblotting.
Cell viability assessment
The cell viability was evaluated by CCK-8 assay (Dojindo
Molecular Technologies, Inc.). BV-2 cells were plated in
the 96-well plates (2.0 × 104 cell per well) and incubated
for 24 h before experiments. The cells were washed with
D-Hanks buffer solution. Two hundred microliters of
CCK-8 solution was added to each well and incubated
for an additional 1 h at 37 °C. The optical density (OD)
of each well at 450 nm was recorded on a Microplate
Reader (Thermo, Varioskan Flash). The cell viability (%
of control) is expressed as the percentage of (ODtest −
ODblank) / (ODcontrol −ODblank), where ODcontrol is the
optical density of the control sample and ODblank is the
optical density of the wells without BV-2 cells.
Tolerance models and behavioral analysis
Animals was habituated in the testing environments for
2 days and carried out behavioral testing in a blinded
manner. For the test of chronic tolerance, mice were
injected with saline or morphine (10 mg/kg) subcutane-
ously every 12 h for 7 days and analgesia was assessed
30 min later by the tail-flick assay [17]. The test was per-
formed by gently holding the mouse in a terry cloth
towel and immersing between 2 and 3 cm from the tip
of the tail into warm water (52 °C). A cutoff time of 10 s
was set to avoid tissue damage. Data were calculated as
percentage of maximal possible effect (% MPE), which
was calculated by the following formula: 100% × [(Drug
response time − Basal response time) / (10 s − Basal re-
sponse time)] = % MPE. The experimenters were blinded
to the treatment. Metformin (50, 100, or 200 mg/kg)
was dissolved in saline and administered intraperitone-
ally 15 min before morphine treatment twice a day from
day 1 to day 7.
NF-κB activation assay
Cells (BV2) were plated in class bottom cell culture
dishes and treated with morphine (200 μM) for 2 h with
or without metformin (100 μM). Cells were fixed with
ice-cold methanol and were permeabilized with 0.25%
Triton X-100/PBST. After blocking with 1% bovine
serum albumin (BSA) in PBST for 1 h, the coverslips
with BV-2 cells were incubated for 2 h at room
temperature with the p65/RelA antibody diluted in 1%
BSA (1:50). Then, the coverslips were exposed to the
fluorescein isothiocyanate (FITC)-conjugated antirabbit
IgG (1:100, at room temperature for 1 h) and then were
rinsed three times with PBS. Finally, the coverslips were
stained with 1 μg/mL DAPI (4′,6-diamidino-2-phenylin-
dole, a fluorescent DNA dye to mark nucleus) for 1 min.
Confocal microscopy analyses were carried out using
Olympus FV1000 confocal system.
Analysis of mRNA levels by quantitative real-time
polymerase chain reaction (PCR)
Cells samples were homogenized in Trizol reagent
(Invitrogen Life Technologies, Carlsbad, CA, USA), and
total RNA was treated by DNaseI and subjected to
quantitative PCR, which was performed with ABI Prism
7300 sequence detection system (Applied Biosystems,
Foster City, CA, USA) using SYBR Green I dye. The
specific primer sequences for IL-1β, IL-6, TNF-α,
TLR4, and GAPDH are listed as follows: IL-1β sense
5′-TCATTGTGGCTGTGGAGAAG-3′, antisense 5′-






GGACGTTTGGCACAT-3′, TGF-β sense 5′-ATGGTG
GACCGCAACAAC-3′, antisense 5′-GCACTGCTTCCC
GAATGTC-3′, Toll-like receptor-4 (TLR-4) sense 5′-
ACTGTTCTTCTCCTGCCTGACA-3′, antisense 5′-
CCTAGTCTTTGAGTCGTTTCAGG-3′, IL-10 sense 5′-
AACATACTGCTAACCGACTC-3′, antisense 5′-GGAT
CATTTCCGATAAGG-3′, GAPDH sense 5′-CAAAA
GGGTCATCTCC-3′, and antisense 5′-CCCCAGCATC
AAAGGTG-3′ GAPDH. Gene was used as an endogen-
ous control to normalize for differences in the amount of
total RNA in each sample.
Western blot
To identify temporal expression level of IBA-1, GAPDH,
IL-1β, TNF-α, and the phosphorylated protein levels of
p38 MAPK, N-methyl-D-aspartic acid receptor NR1
(NMDAR-NR1), PKCγ, protein samples were analyzed
as described before. In brief, samples (cells or spinal cord
tissue segments at L1-L6) were collected and washed with
ice-cold PBS before being lysed in radio immunoprecipita-
tion assay (RIPA) lysis buffer [Beyotime, Shanghai, China;
50 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% Triton X-
100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 1 mmol/L phenylmethylsulfonyl fluoride, 0.15 U/
mL aprotinin, and 1 mg/mL pepstatin] and then sample
lysates were separated by SDS-PAGE and electrophoretic-
ally transferred onto polyvinylidene fluoride membranes
(Millipore Corp., Bedford, MA, USA). The membranes
were blocked with 10% whole milk in TBST (Tris-Hcl,
NaCl, Tween 20) for 2 h at room temperature, probed
with primary antibodies at 4 °C overnight [GAPDH,
1:8000; IBA-1, 1:1000; IL-1β, 1:1000; TNF-α, 1:1000;
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p-p38 (Tyr182), 1:1000; p-NR1(Ser896), 1:1000; p-PKCγ,
1:1000] and then incubated with horseradish peroxidase-
coupled secondary antibodies from Cell Signaling Tech-
nology (Beverly, MA, USA). Data were acquired with the
Molecular Imager (Gel DocTM XR, 170–8170) and ana-
lyzed with Quantity One-4.6.5 (Bio-Rad Laboratories,
Berkeley, CA, USA).
Immunofluorescence assay
After anesthesia by intraperitoneal injection of sodium
pentobarbital (100 mg/kg), the animal was perfused
with normal saline followed by 4% paraformaldehyde in
0.1 M PBS, pH 7.2–7.4, for 20 min. Then, L4 and/or L5
lumbar segment were dissected out and post-fixed in
the same fixative. The embedded blocks were sectioned
as 30 μm thick and processed for immunofluorescence
assay. Sections from each group (five mice in each
group) were incubated with primary antibody (IBA-1,
1:200; c-fos, 1:200; CGRP, 1:200). Then, the free-floating
sections were washed with PBS and incubated with the
secondary antibody (1:300; Jackson Laboratories, USA)
for 2 h at room temperature. After using PBS to wash
three times, the samples were investigated with a con-
focal microscope (Leica TCS SPEII, Leica Biosystems,
Wetzlar, Germany) for morphologic details. Images
were randomly coded and transferred to a computer
for analysis.
Statistical analysis
SPSS Rel 15 (SPSS Inc., Chicago, IL, USA) was used to
conduct all the statistical analyses. Data were statistically
evaluated by two-way analysis of variance (ANOVA)
followed by Bonferroni post hoc tests. The mean fluores-
cent pixels of IBA-1 and CGRP were measured by Image
Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD,
USA). Results were represented as mean ± SEM of three
independent experiments. Results described as signifi-
cant were based upon a criterion of p < 0.05.
Results
Metformin inhibits the inflammation induced by morphine
in BV-2 cells
To investigate the effects of metformin on morphine-in-
duced microglial activation in vitro, immortalized murine
microglial cell line BV-2 cells were used. As shown in
Fig. 1, morphine (200 μmol/L, 6 h) significantly induced
the activation of BV-2 cells, which was characterized by
up-regulated mRNA expression of pro-inflammatory cyto-
kines (including IL-1β, IL-6, TNF-α, and TLR4), increased
phosphorylation of p38 MAPK. Metformin administration
before morphine significantly decreased these effects.
In addition, we also examined the potential effects of
metformin on anti-inflammatory cytokines (including TGF-
β, IL-4, and IL-10). Morphine did not affect the mRNA
expression of anti-inflammatory cytokines, and metformin
Fig. 1 Metformin inhibited morphine-induced inflammation in microglial BV-2 cells. Cells were pretreated with metformin (4, 20, or 100 μM) for
15 min before the challenge of morphine (200 μM). BV-2 cells were collected and analyzed 6 h after morphine was given. a–c Metformin suppressed
the expression of pro-inflammatory factors induced by morphine in BV-2 cells in a dose-dependent manner (n = 4). The levels of IL-1β, IL-6, and TNF-α
mRNA were determined using real-time quantitative polymerase chain reaction (PCR). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as an invariant control. d Metformin inhibited the phosphorylation of p38 induced by morphine treatment in BV-2 cells in a dose-dependent manner
(n = 4). e Metformin suppressed TLR-4 mRNA expression induced by morphine in BV-2 cells in a dose-dependent manner (n = 4). The level of TLR-4
mRNA was determined with real-time quantitative PCR. (*p < 0.05; **p < 0.01 Bonferroni post hoc tests)
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also had no significant effects on the expression of cytokines
(Additional file 1 Fig. S1A, B and C). MTT test showed that
morphine or metformin did not affect cell viability in
BV-2 cells.
Metformin inhibits microglial activation induced by
morphine through AMPK activation
Previous studies have shown that metformin has been
shown to function through activation of AMPK [18]. There-
fore, we tested whether metformin inhibited microglial acti-
vation through AMPK activation in BV-2 cells. As shown in
Fig. 2f, metformin increased phosphorylation of AMPK at
Thr172 in a dose-dependent manner. Furthermore, we
assessed whether AMPK inhibition could abolished the
effects of metformin on morphine-induced microglia activa-
tion (Fig. 2a–e). We found that the AMPK inhibitor com-
pound C significantly reversed the effects of metformin.
Metformin inhibited the translocation of p65 NF-κB from
the cytoplasm to the nucleus induced by morphine, which
was also abolished by compound C (Fig. 3). These data
showed that metformin inhibited microglial activation in-
duced by morphine through AMPK signaling pathway.
Metformin inhibits IL-6 mRNA expression in bEnd3 cells
treated with morphine
Recent studies have demonstrated that microvascular
endothelial cells take part in the development of
morphine-induced neuroinflammation and tolerance [19].
Therefore, we tested whether metformin regulate the ex-
pression of pro-inflammatory cytokines, chemokine ligand
2 (CCL2), and TLR4 in morphine-treated bEnd3 cells. As
shown in Fig. 4, we found that morphine and metformin
both did not affect the expression of TLR4, CCL2, and IL-
1β, but metformin decreased the mRNA expression of IL-
6 and TNF-α induced by morphine. These data showed
that metformin did not markedly regulate microvascular
endothelial cells when reducing morphine tolerance.
Metformin attenuates chronic morphine tolerance in mice
To test the effects of metformin on morphine tolerance
in vivo, i.t. injection of morphine (10 mg/kg, given sub-
cutaneously each day for 7 days) was used to induce
tolerance in mice. As shown in Fig. 5a, c, metformin
[up to 200 mg/kg, intraperitoneal (i.p.), 15 min before
each injection of morphine on each day] did not affect
the pain threshold or the initial morphine-induced an-
algesia. However, repetitive metformin treatment sig-
nificantly reduced the decreased analgesia resulted by
morphine in a dose-dependent manner (Fig. 5b, d).
These data showed that metformin is effective in at-
tenuating chronic morphine tolerance.
Metformin reduces spinal microglial activation in mice
treated with chronic morphine
To investigate the mechanism of metformin in reducing
morphine tolerance in vivo, we tested the expression of
Fig. 2 Metformin inhibits microglial activation induced by morphine through AMPK activation. a, b, c, e AMPK inhibitor compound C (20 μM)
abolished the inhibition effects of metformin on the mRNA expression of IL-1β, IL-6, TNF-α, and TLR-4 in morphine-activated BV-2 cells (n = 4).
d AMPK inhibitor compound C (20 μM) abolished the inhibition effects of metformin on the phosphorylation of p38 MAPK induced by morphine
in BV-2 cells (n = 4). f Metformin increased phosphorylation of AMPK at Thr172 in BV2 cells in a dose-dependent manner. BV2 cells were collected
and analyzed 6 h after incubation with metformin (4, 20, and 200 μM) (n = 4). (*p < 0.05; **p < 0.01; Bonferroni’s post hoc tests)
Pan et al. Journal of Neuroinflammation  (2016) 13:294 Page 5 of 12
microglial activation marker IBA-1 in the spinal cord
and measured the states of microglia. Our western blot
and immunofluorescence data showed that repeated
morphine exposure (10 mg/kg, given subcutaneously
each day for 7 days) showed significant microglial acti-
vation in the spinal cord. The activation was manifested
as an up-regulated IBA-1 protein level (Fig. 6a, b) and
an increased IBA-1 fluorescence density (Fig. 6c, d).
Metformin (200 mg/kg) significantly inhibited microglial
activation induced by morphine. These data indicated
that pretreatment with metformin could suppress the
activation of spinal microglia induced by chronic mor-
phine exposure in vivo.
Once activated, microglia release a large number of
pro-inflammatory cytokines to induce inflammatory
response. Therefore, we tested whether metformin regu-
late neuroinflammation induced by morphine. Similar to
the results in vitro, metformin (50, 100, and 200 mg/kg)
increased the phosphorylation of AMPK at Thr172 in a
dose-dependent manner (Fig. 7a). Morphine significantly
Fig. 3 Metformin inhibited morphine-induced NF-κB (p65) activation in microglial BV-2 cells. Metformin (100 μM) attenuated the translocation of
NF-κB (p65) from the cytosol to the nucleus after morphine treatment. The effects of metformin were abolished by the AMPK inhibitor compound
C (n = 4). NF-κB activity was analyzed by p65 nuclear translocation assay. Original magnification, ×400. Significant difference was revealed following
one-way analysis of variance (**p < 0.01; Bonferroni’s post hoc tests)
Fig. 4 Metformin did not markedly affect morphine-induced inflammation in bEND3 cells. a–c Morphine with or without metformin treatment
showed no notable effects on mRNA expression of TLR4, CCL2, and IL-1β in bEND3 cells (n = 4). d, e Morphine increased the mRNA expression of
IL-6 and TNF-α, which were decreased by metformin treatment (100 and 200 μM) (n = 4). The levels of mRNA were determined using real-time
quantitative polymerase chain reaction (PCR)
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increased the expression of TLR4 mRNA, p-p38, IL-1β,
and TNF-α protein in vivo, which were inhibited by met-
formin (100 and 200 mg/kg) (Fig. 7b–d). These data sug-
gested that metformin could suppress neuroinflammation
induced by morphine through AMPK-mediated signaling.
Metformin attenutates central sensitization induced by
morphine through reducing phosphorylation of NR1
and PKCγ
The NMDA receptor, which regulates neuronal activity
and synaptic efficacy, plays an important role in inflamma-
tory response. NMDA receptor phosphorylation can be
activated by pro-inflammatory factors and phosphorylated
by protein kinase C (PKC). Thus, we examined whether
metformin regulate phosphorylation of NR1 and PKCγ
in the spinal cord to reduce inflammatory response. As
shown in Fig. 8a, morphine markedly increased phos-
phorylation of NR1 and PKCγ, which were inhibited by
metformin in a dose-dependent manner.
Metformin inhibits phosphorylation of c-fos and CGRP in
morphine-treated mice
Furthermore, we measured the expression of morphine
tolerance indicators c-fos and CGRP in the spinal cord
using immunofluorescence staining. As shown in Fig. 8b,
the c-fos and CGRP level were significantly increased
induced by morphine compared with sham group.
Treatment with metformin (200 mg/kg) suppressed the
increase of the c-fos and CGRP level. These results further
explained that metformin could attenuate morphine
tolerance in vivo.
Discussion
In our study, we found that metformin, a potent antihy-
perglycaemic agent and AMPK activator, had a significant
inhibitory effect on morphine-induced microglial acti-
vation. Metformin inhibited the morphine-induced up-
regulation of p38 MAPK phosphorylation, NF-κB nuclear
translocation, and proinflammatory cytokine expression in
microglia, which were abolished by AMPK inhibition.
Thus, metformin significantly attenuated the development
of chronic morphine tolerance in an efficient manner. The
study may provide a new solution by inhibiting microglial
activation through increasing AMPK activation to im-
prove clinical analgesic efficacy of morphine.
Non-neuronal cells, especially microglia, are crucial in
the pathogenesis of morphine tolerance [20]. Microglial
activation has been shown to play an important role in
cytokine release in the CNS [21]. After chronic or acute
exposure to morphine, activated microglia exhibit in-
creased expression of pro-inflammatory cytokines, such
as IL-1β, IL-6, TNF-α, and chemokines [22, 23]. These
changes contribute to morphine analgesic tolerance. In
the present study, we found that morphine increased
the mRNA expression of IL-1β, IL-6, and TNF-α in BV-
2 cells (Fig. 1a–c). Interestingly, metformin, a potent
Fig. 5 Metformin attenuated chronic morphine tolerance. Tail-flick method was performed to evaluate the effect of metformin on the morphine
tolerance. Data were shown as percentage of maximal possible effect (% MPE). Twelve mice were included in each group. a, c Metformin (50,
100, and 200 mg/kg, i.p.) exhibited no effects on the initial analgesic response to morphine (10 mg/kg, s.c.) (n = 8). b, d Metformin suppressed
chronic morphine tolerance (n = 8) (*p < 0.05; **p < 0.01; Bonferroni’s post hoc tests). Metformin was administered intraperitoneally daily 15 min
before each morphine injection
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antihyperglycemic agent, was found to inhibit cytokines
production induced by morphine (Fig. 1), and AMPK
inhibition abolished the effects of metformin (Fig. 2a–c).
These data suggest that metformin may be beneficial to
reducing microglial activation and morphine tolerance.
Previous studies have shown that both pro-inflammatory
and anti-inflammatory cytokines are involved in the
development and maintenance of morphine tolerance [22,
24, 25]. IL-4, IL-10, and TGF-β are powerful anti-
inflammatory cytokines with a wide spectrum of biological
effects [26–28]. Therefore, we tested whether met-
formin inhibit inflammatory response via regulating
anti-inflammatory cytokines production. In accordance
with the previous study [26], we found that morphine did
not affect the expression of anti-inflammatory cytokines
mRNA level. However, metformin did not increase anti-
inflammatory cytokines mRNA level (Fig. S1). These data
suggest that the effects of metformin are mainly relates to
the regulation of pro-inflammatory cytokines.
It is well known that NF-κB has diverse and compli-
cated effects on the immune response and nervous sys-
tems [29, 30]. Activation of NF-κB is one of the major
events following the onset of an inflammatory response
mainly initiated by proinflammatory cytokines [31]. Acti-
vation of NF-κB also induces production of cytokines
that activate NF-κB in cancer cells to induce chemokines
that attract more inflammatory cells into the tumor [32].
Morphine can induce the translocation of NF-κB p65
from the cytosol to the nucleus, and NF-κB inhibition
can reverse the mRNA expression of IL-1β, IL-6, and
TNF-α following morphine treatment [33]. Therefore,
NF-κB is an important transcription factor and plays
critical roles in inflammation. Our study showed that
morphine markedly increased NF-κB p65 level in the
Fig. 6 Metformin attenuated spinal microglial activation in chronic morphine administration. Morphine was injected subcutaneously (10 mg/kg)
once a day for 7 days; metformin (200 mg/kg) was administered intraperitoneally daily 15 min before each morphine injection. The lumbar spines
(L1–L6) were collected and analyzed 120 min after the last morphine administration. a, b Metformin inhibited up-regulation IBA-1 protein
expression induced by chronic morphine treatment in the spinal cord (n = 4). c, d Metformin inhibited expression of IBA-1 induced by chronic
morphine (n = 4). Confocal images and immunofluorescence analysis data showed IBA-1 in the dorsal horns (scale bar, 100 μm). Quantification
of IBA1 immunofluorescence was represented as mean fluorescence pixels in the superficial dorsal horns (n = 5, 5 images per animal) (*p < 0.05;
**p < 0.01; Bonferroni’s post hoc tests)
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Fig. 7 Metformin inhibits the inflammation induced by morphine in vivo. a Metformin increased AMPK-Tyr172 phosphorylation in mice spinal
cords in a dose-dependent manner (n = 4). b Metformin inhibited morphine-induced up-regulation of TLR-4 mRNA in spinal cords (n = 4). c Metformin
inhibited morphine-induced up-regulation of p38 phosphorylation in spinal cords (n = 4). d Metformin inhibited morphine-induced IL-1β and TNF-α
protein expression in spinal cords (n = 4). The lumbar spines (L1–L6) were collected and analyzed 15 min after metformin (50, 100, and 200 mg/kg, i.p.)
administration. Significant difference was revealed following one-way analysis of variance (*p < 0.05; **p < 0.01; Bonferroni’s post hoc tests)
Fig. 8 Metformin inhibits phosphorylation of c-fos and CGRP in the STN. a Metformin reduces morphine-induced phosphorylation of NR1 and
PKCγ in vivo (n = 4). b, c Immunofluorescence analysis data show CGRP expression and c-fos-immunoreactive neurons number. The CGRP and
c-fos level were significantly increased by morphine; metformin (200 mg/kg) suppressed the increase of CGRP expression and attenuated the
increase of c-fos-immunoreactive neurons number. n = 5, five images per animal. Significant difference was revealed following one-way analysis
of variance (*p < 0.05; **p < 0.01; Bonferroni’s post hoc tests)
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nucleus, which was reversed by metformin (Fig. 3).
These data suggest that metformin may decrease the cy-
tokines production via inhibiting activation of NF-κB.
Recent studies have demonstrated that the MAPK
family, including p38 MAPK, extracellular signal-
regulated protein kinase (ERK), and c-Jun N-terminal
kinase, plays important roles in morphine tolerance
[34–36]. The expression of pro-inflammatory cytokines
and other harmful signaling molecules is regulated by
p38 MAPK/NF-κB signaling pathway in the CNS [37].
Microglia inhibitor minocycline and p38 inhibitor
SB203580 markedly attenuate morphine-induced pro-
inflammatory cytokines production and inhibit morphine
tolerance [38, 39]. We found that morphine increased
p38 MAPK phosphorylation, which was decreased by
metformin (Fig. 1d). The effect of metformin was abol-
ished by AMPK inhibitor (Fig. 2d). In addition, compel-
ling evidence has suggested that morphine induces
microglial activation through binding with the Toll-like
receptor 4 (TLR4) expressed in spinal microglia, activat-
ing downstream intracellular signaling pathways, leading
to the release of cytokines and suppression of inflamma-
tory response. TLR4 also plays a critical role in p38
phosphorylation induced by morphine. In our study, we
found that morphine treatment significantly increased
the mRNA expression of TLR4 in BV-2 cells, which was
abolished by metformin (Fig. 1e). These findings suggest
that TLR4/p38 MAPK signaling pathway was involved
in the protection effects of metformin. Metformin
inhibit microglial activation via reducing the morphine-
induced mRNA expression of TLR 4 and proinflamma-
tory cytokines. Consistent with our findings, Eidson and
Murphy reported that blockade of TLR 4 attenuates
morphine tolerance and facilitates the pain relieving
properties of morphine [7].
Several studies have indicated that microvascular
endothelial cells could be involved in morphine-induced
neuroinflammation and play an important role [40, 41]. We
tested whether metformin-attenuated morphine toler-
ance relate to regulating states of microvascular endo-
thelial cells. We found that metformin did not affect
the expression of CCL2, TLR4, and IL-1β. However,
metformin significantly decreased the upregulation of
IL-6 and TNF-α mRNA level induced by morphine
(Fig. 4d, e). These data showed that regulation of IL-6
and TNF-α mRNA level by metformin in microvascular
endothelial cells was partially involved in the attenu-
ation of morphine tolerance.
Furthermore, we investigated whether metformin could
attenuate morphine tolerance in vivo. In the present study,
behavioral tests showed that the mice developed allodynia
and hyperalgesia following morphine withdrawal (Fig. 5).
Metformin reduced chronic morphine tolerance in a
dose-dependent manner. Previous studies have shown that
expression of the microglial maker IBA-1 is significantly
increased when microglia are activated. Our data showed
that resveratrol notably inhibited microglial activation,
suppressing the up-regulated IBA-1 expression in the
spinal dorsal horn (Fig. 6).
The NMDA receptor, regulating neuronal activity and
synaptic efficacy, plays an important role in various in-
flammation states [21]. The NMDA receptor 1 (NR1) is
preferentially phosphorylated by PKCγ [42]. PKCγ acti-
vation plays well-developed role on central sensitization
in morphine tolerance, which may contribute to increas-
ing the excitability of nociceptive neurons [43]. Our re-
sults showed that metformin provide an inhibition in the
activation of PKCγ and the phosphorylation of NMDA re-
ceptors NR1 in morphine tolerance mice (Fig. 8a). These
data suggest that metformin may inhibit microglial activa-
tion and further suppress central sensitization occurring
in the spinal cord, which contribute to the attenuation of
morphine tolerance. In addition, calcitonin gene-related
peptide (CGRP) and c-fos have been implicated in pain
transmission and morphine tolerance [44–46] and have
been considered as the indicators of morphine tolerance.
It is widely distributed in central nervous system and per-
ipheral organs in rodents. Our group has demonstrated
that the increase of CGRP and c-fos release induced by
morphine could be almost completely abolished by met-
formin (Fig. 8b). These data suggest that metformin could
be an operative medicine to attenuate morphine tolerance.
Conclusions
In this study, we provided the evidence for the first time
that metformin, a biguanide class of antidiabetic drugs,
could extend morphine analgesia and improve chronic
morphine tolerance. We have illustrated the possible
mechanism by which metformin inhibited microglial
activation and attenuated morphine tolerance. Our data
showed that metformin inhibits microglial activation and
relieves microglia-mediated neuroinflammation via AMPK
activation and further suppresses central sensitization
occuring in the spinal cord and reduces morphine toler-
ance. Therefore, our study may potentially offer a new
clinical application of metformin in morphine tolerance
and suggest that AMPK may be a target of clinical treat-
ment in attenuating morphine tolerance.
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